Samsung Biologics to build new plant in Incheon

Показать описание

삼성바이오로직스, 송도에 4공장 신설… 2만7000명 일자리 창출

The biopharmaceutical unit of the nation's biggest conglomerate unveiled plans to build its fourth plant.
The new facility in Incheon is looked to maximize Samsung Biologics' operational efficiency and manufacturing capabilities while imposing an even bigger global presence.
Kim Ji-yeon provides a glimpse of what to expect.
Samsung Biologics, Samsung Group's biopharmaceutical unit, has laid out plans to build its fourth plant in South Korea to meet rising orders.
It looks to begin construction of the one-point-five billion U.S. dollar plant in Incheon's Songdo District during the latter half of this year.
At 238-thousand square-meters, the new plant is larger than all three of Samsung Biologics' current plants put together.
The total size of the investment is more than the total amount invested in the company's previous three plants combined.
The new plant will bring Samsung Biologics' total bioreactor capacity to 620-thousand liters, making it the largest contract biopharmaceutical manufacturer in the world.
The plant will focus on cell line development... which is used for mass production of antibody drugs, and assembling parts for finished products and materials for clinical testing.
With this, Samsung Biologics hopes to seize some 30-percent of the global bio contract manufacturing market share.
The plant is expected to help create nearly 27-thousand jobs in total... and bring more than four-point-seven-billion dollars of economic benefits.
The company has inked a combined 850-million dollars worth of deals to manufacture products for major global pharmaceutical giants during the first half of this year.
Kim Ji-yeon, Arirang News.

#Samsung #Biologic #build